Canbridge Pharmaceuticals Inc

CANbridge Pharmaceuticals Inc. is a biopharmaceutical company that researches, develops, and commercializes therapies for rare diseases and oncology indications worldwide. Its products include Hunterase, an enzyme replacement therapy for Hunter syndrome, and Livmarli, an oral inhibitor for Alagille syndrome and progressive familial intrahepatic cholestasis. The company is developing CAN106 for paroxysmal nocturnal hemoglobinuria, CAN103 for Gaucher disease, CAN107 for X-linked hypophosphatemia, CAN104 for Fabry disease, CAN105 for hemophilia A, and CAN204 for Duchenne muscular dystrophy. It has a license agreement with Mirum Pharmaceuticals for Livmarli and was founded in 2012, headquartered in Suzhou, China.